Robert Mayer, PhD

Dr. Robert Mayer has completed his degree at the University of Innsbruck in the field of analytical chemistry, where he was mainly dealing with plants and plant extract to determine their antibacterial activities. After completion, he joined Sandoz GmbH in 2009 in the position as laboratory head in the working group for protein characterization. Since 2010 Robert Mayer has been the responsible project analyst for the biosimilar product GP2015, which was recently approved by the FDA, EMA and Health Canada as a biosimilar to Enbrel®.